Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW9135
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GW9135 is a **PPARpan agonist**, a small molecule compound that activates all three subtypes of peroxisome proliferator-activated receptors (PPARα, PPARγ, and to a lesser extent, PPARδ). It shows highest potency at PPARα and significant activity at PPARγ, with weaker potency at PPARδ. GW9135 has demonstrated the ability to induce transient weight loss and reduce fat mass in animal models, but with compensatory weight regain during continued dosing. Like other strong PPAR agonists, it also increases liver weight. It is used primarily as a research compound to study metabolic and obesity-related processes.[1][3]
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on GW9135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GW9135.